EMA calls for companies to trace their heparin to slaughterhouses

By Nick Taylor

- Last updated on GMT

Related tags: Ema, Manufacturing

EMA calls for companies to trace their heparin to slaughterhouses
Marketing applications for heparin should cover traceability from slaughterhouses and other details of sourcing porcine mucosa, the EMA said.

The European Medicines Agency (EMA) made the statement in a reflection paper​ intended to clarify the variability allowed when sourcing starting materials and intermediates from living organisms.

“Variability in sourcing and initial manufacturing steps has traditionally been allowed in contrast to the well characterised biotechnological products of recombinant origin for which the declared manufacturing process starts from a unique and well identified cell bank system”​, the EMA wrote.

Before allowing such variability the EMA wants details of the manufacturing processes. Companies should list and justify any different purification steps, process conditions, and equipment used by suppliers.

The EMA uses heparin as an example. “The marketing authorisation dossier should cover the whole manufacturing process starting from the sourcing of the mucosa. Aspects with potential impact on product quality and safety needs to be presented in sufficient detail”​, the EMA wrote.

Details requested by the EMA include species and country of origin, traceability from abattoirs, and confirmation that the animals used are fit for human consumption. The other examples given by the EMA are urine- and plasma-derived products.

Variable suppliers

While acknowledging the need for “some flexibility within the 'one process = one product' paradigm”​ the EMA wants to define what is acceptable. By allowing some differences the EMA hopes to make it easier for manufacturers to find multiple suppliers and minimise the risk of drug shortages.

“These first steps of collection, testing and pre-treatment of the starting material may be carried out by different suppliers who could apply different processes to obtain an 'early intermediate'”​, the EMA wrote.

When using suppliers with different processes manufacturers should make sure their own production steps are robust enough to ensure the drug is the same, regardless of the intermediate used.

“It should be shown that comparable products are consistently obtained in terms of relevant quality attributes irrespective of the process applied. Discernible differences in quality attributes should be discussed and justified in terms of product quality”​, the EMA wrote.

Related news

Show more

Related products

show more

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers

Follow us


View more